FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 20.19 -0.25 (1.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.44 | 52 Week High | $42.49 | |||
| Open | $20.44 | 52 Week Low | $16.64 | |||
| Day High | $20.57 | P/E | N/A | |||
| Day Low | $20.10 | EPS | $-0.42 | |||
| Volume | 1,409,869 | |||||
